Eleven patients took part in a two-month trial of the treatment. Nine completed the treatment, and seven of these responded to treatment, according to developers, Inkine Pharmaceuticals of Blue Bell, Pennsylvania, USA.
Two patients were unable to complete the trial because of adverse events: one suffered an allergic reaction to the drug, while the other, who had pre-existing sclerosing cholangitis, had to be hospitalized for jaundice.
The drug, a steroid molecule formerly known as CBP-1011, has already had a successful phase II clinical trial for the treatment of Crohn's disease.
Dr Martin Rose, Inkine's executive vice-president for research and development, said: "We find these results highly encouraging, especially in light of response rates of the most recently approved drugs for ulcerative colitis.
"These therapies have been approved with response rates ranging between 37 per cent and 71 per cent. Given our results, we plan to move Colirest into later stage pivotal trials."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com